CN106842617A - 光学器件 - Google Patents
光学器件 Download PDFInfo
- Publication number
- CN106842617A CN106842617A CN201710022994.0A CN201710022994A CN106842617A CN 106842617 A CN106842617 A CN 106842617A CN 201710022994 A CN201710022994 A CN 201710022994A CN 106842617 A CN106842617 A CN 106842617A
- Authority
- CN
- China
- Prior art keywords
- filter
- optical
- light
- selective
- porphyrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003287 optical effect Effects 0.000 claims abstract description 234
- 239000000758 substrate Substances 0.000 claims abstract description 127
- 238000001914 filtration Methods 0.000 claims abstract description 35
- 238000001429 visible spectrum Methods 0.000 claims abstract description 31
- 230000001629 suppression Effects 0.000 claims abstract description 22
- 230000005540 biological transmission Effects 0.000 claims description 58
- -1 Porphyrin compound Chemical class 0.000 claims description 36
- 150000004032 porphyrins Chemical class 0.000 claims description 24
- 239000000975 dye Substances 0.000 claims description 22
- 239000000049 pigment Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 13
- 238000001228 spectrum Methods 0.000 claims description 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 claims description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 5
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 5
- 229960000286 proflavine Drugs 0.000 claims description 5
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 claims description 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 4
- KSCQDDRPFHTIRL-UHFFFAOYSA-N auramine O Chemical compound [H+].[Cl-].C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 KSCQDDRPFHTIRL-UHFFFAOYSA-N 0.000 claims description 4
- 229930002869 chlorophyll b Natural products 0.000 claims description 4
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 claims description 4
- 150000004696 coordination complex Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 235000010930 zeaxanthin Nutrition 0.000 claims description 4
- 239000001775 zeaxanthin Substances 0.000 claims description 4
- 229940043269 zeaxanthin Drugs 0.000 claims description 4
- XPOIQAIBZGSIDD-UHFFFAOYSA-M 2-[4-(dimethylamino)styryl]-1-methylpyridinium iodide Chemical compound [I-].C1=CC(N(C)C)=CC=C1\C=C\C1=CC=CC=[N+]1C XPOIQAIBZGSIDD-UHFFFAOYSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- PIMVUSLRFVRIMZ-UHFFFAOYSA-N [Mg].C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC Chemical compound [Mg].C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC PIMVUSLRFVRIMZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 229930002868 chlorophyll a Natural products 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DGWSNUKQRDJSLY-UHFFFAOYSA-N C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC.[Zn] Chemical compound C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC.[Zn] DGWSNUKQRDJSLY-UHFFFAOYSA-N 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- HCIIFBHDBOCSAF-UHFFFAOYSA-N octaethylporphyrin Chemical compound N1C(C=C2C(=C(CC)C(C=C3C(=C(CC)C(=C4)N3)CC)=N2)CC)=C(CC)C(CC)=C1C=C1C(CC)=C(CC)C4=N1 HCIIFBHDBOCSAF-UHFFFAOYSA-N 0.000 claims description 2
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 claims 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 claims 2
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 claims 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- POXIZPBFFUKMEQ-UHFFFAOYSA-N 2-cyanoethenylideneazanide Chemical group [N-]=C=[C+]C#N POXIZPBFFUKMEQ-UHFFFAOYSA-N 0.000 claims 1
- SVXAETOZIMXUFU-UHFFFAOYSA-N C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.CC2=C(C(=C(C=C2)[Zn])C)C Chemical class C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.CC2=C(C(=C(C=C2)[Zn])C)C SVXAETOZIMXUFU-UHFFFAOYSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 208000035199 Tetraploidy Diseases 0.000 claims 1
- 150000001454 anthracenes Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005595 deprotonation Effects 0.000 claims 1
- 238000010537 deprotonation reaction Methods 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 150000004866 oxadiazoles Chemical class 0.000 claims 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- GJWJYZYRBDJBHK-UHFFFAOYSA-N quinoline;sodium Chemical compound [Na].N1=CC=CC2=CC=CC=C21 GJWJYZYRBDJBHK-UHFFFAOYSA-N 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000011265 semifinished product Substances 0.000 claims 1
- 150000005199 trimethylbenzenes Chemical class 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
- 201000010099 disease Diseases 0.000 description 45
- 206010064930 age-related macular degeneration Diseases 0.000 description 40
- 208000002780 macular degeneration Diseases 0.000 description 40
- 208000010412 Glaucoma Diseases 0.000 description 39
- 230000004224 protection Effects 0.000 description 37
- 238000000034 method Methods 0.000 description 32
- 206010012689 Diabetic retinopathy Diseases 0.000 description 30
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 21
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 20
- 239000010408 film Substances 0.000 description 19
- 210000003994 retinal ganglion cell Anatomy 0.000 description 19
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 18
- 230000004438 eyesight Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 231100000760 phototoxic Toxicity 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 16
- 238000010586 diagram Methods 0.000 description 15
- 239000004038 photonic crystal Substances 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 14
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 13
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 13
- 239000011358 absorbing material Substances 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 238000002834 transmittance Methods 0.000 description 12
- 229960003987 melatonin Drugs 0.000 description 11
- 230000037072 sun protection Effects 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 208000001491 myopia Diseases 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 230000009931 harmful effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000000737 periodic effect Effects 0.000 description 9
- 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 description 8
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 210000001747 pupil Anatomy 0.000 description 8
- 239000010409 thin film Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 206010034972 Photosensitivity reaction Diseases 0.000 description 7
- 230000027288 circadian rhythm Effects 0.000 description 7
- 230000006866 deterioration Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000007578 phototoxic dermatitis Diseases 0.000 description 7
- 231100000018 phototoxicity Toxicity 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 description 7
- 239000005020 polyethylene terephthalate Substances 0.000 description 7
- 239000004814 polyurethane Substances 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- 230000002207 retinal effect Effects 0.000 description 7
- 230000003595 spectral effect Effects 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000012994 photoredox catalyst Substances 0.000 description 5
- 230000004296 scotopic vision Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 239000004986 Cholesteric liquid crystals (ChLC) Substances 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- VMJKUPWQKZFFCX-UHFFFAOYSA-N coumarin 504 Chemical compound C1CCC2=C(OC(C(C(=O)OCC)=C3)=O)C3=CC3=C2N1CCC3 VMJKUPWQKZFFCX-UHFFFAOYSA-N 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 4
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- YLYPIBBGWLKELC-RMKNXTFCSA-N 2-[2-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC(=C(C#N)C#N)C=C(C)O1 YLYPIBBGWLKELC-RMKNXTFCSA-N 0.000 description 3
- ZHBOFZNNPZNWGB-UHFFFAOYSA-N 9,10-bis(phenylethynyl)anthracene Chemical compound C1=CC=CC=C1C#CC(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C#CC1=CC=CC=C1 ZHBOFZNNPZNWGB-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000004456 color vision Effects 0.000 description 3
- KCDCNGXPPGQERR-UHFFFAOYSA-N coumarin 343 Chemical compound C1CCC2=C(OC(C(C(=O)O)=C3)=O)C3=CC3=C2N1CCC3 KCDCNGXPPGQERR-UHFFFAOYSA-N 0.000 description 3
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000002592 gangliocyte Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 3
- 238000001020 plasma etching Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- UDBAOKKMUMKEGZ-UHFFFAOYSA-K trichloromanganese Chemical compound [Cl-].[Cl-].[Cl-].[Mn+3] UDBAOKKMUMKEGZ-UHFFFAOYSA-K 0.000 description 3
- 230000016776 visual perception Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UWAUSMGZOHPBJJ-UHFFFAOYSA-N 4-nitro-1,2,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=NO2 UWAUSMGZOHPBJJ-UHFFFAOYSA-N 0.000 description 2
- UQASJTNIEXIESH-UHFFFAOYSA-N 5,10,15,20-tetrakis(2,6-dichlorophenyl)-21,23-dihydroporphyrin Chemical compound Clc1cccc(Cl)c1-c1c2ccc(n2)c(-c2c(Cl)cccc2Cl)c2ccc([nH]2)c(-c2c(Cl)cccc2Cl)c2ccc(n2)c(-c2c(Cl)cccc2Cl)c2ccc1[nH]2 UQASJTNIEXIESH-UHFFFAOYSA-N 0.000 description 2
- PJOJZHHAECOAFH-UHFFFAOYSA-N 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin Chemical compound COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 PJOJZHHAECOAFH-UHFFFAOYSA-N 0.000 description 2
- GTZCNONABJSHNM-UHFFFAOYSA-N 5,10,15,20-tetraphenyl-21,23-dihydroporphyrin zinc Chemical compound [Zn].c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 GTZCNONABJSHNM-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000004983 Polymer Dispersed Liquid Crystal Substances 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000038018 age-related macular disease Diseases 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003669 anti-smudge Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004313 glare Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 230000005043 peripheral vision Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FDJUBNCEVCSIAV-UHFFFAOYSA-N tetrakis(o-aminophenyl)porphyrin Chemical compound NC1=CC=CC=C1C(C1=CC=C(N1)C(C=1C(=CC=CC=1)N)=C1C=CC(=N1)C(C=1C(=CC=CC=1)N)=C1C=CC(N1)=C1C=2C(=CC=CC=2)N)=C2N=C1C=C2 FDJUBNCEVCSIAV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000411 transmission spectrum Methods 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- IZPNVUYQWBZYEA-UHFFFAOYSA-N 1,4-dimethylpyridin-1-ium Chemical compound CC1=CC=[N+](C)C=C1 IZPNVUYQWBZYEA-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- MYHWPJUOBDUCFW-UHFFFAOYSA-N CC1=C(C(=C(C=C1)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C1=C(C(=C(C=C1)C)C)C)N=4)C1=C(C(=C(C=C1)C)C)C)N3)C1=C(C(=C(C=C1)C)C)C)=N2)C)C Chemical compound CC1=C(C(=C(C=C1)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C1=C(C(=C(C=C1)C)C)C)N=4)C1=C(C(=C(C=C1)C)C)C)N3)C1=C(C(=C(C=C1)C)C)C)=N2)C)C MYHWPJUOBDUCFW-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- QCWPXJXDPFRUGF-UHFFFAOYSA-N N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 Chemical compound N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 QCWPXJXDPFRUGF-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 238000001015 X-ray lithography Methods 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- HJTAXGKRJGUCNN-UHFFFAOYSA-N [Mg].c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 Chemical compound [Mg].c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 HJTAXGKRJGUCNN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- VFHDWGAEEDVVPD-UHFFFAOYSA-N chembl507897 Chemical compound C1=CC(O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(O)=CC=1)=C1C=CC(=N1)C(C=1C=CC(O)=CC=1)=C1C=CC(N1)=C1C=2C=CC(O)=CC=2)=C2N=C1C=C2 VFHDWGAEEDVVPD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000003280 chronobiological effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- USIHEAIUCFLGKK-UHFFFAOYSA-N cobalt(2+) 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin Chemical compound [Co++].COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 USIHEAIUCFLGKK-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- WUPRCGRRQUZFAB-DEGKJRJSSA-N corrin Chemical compound N1C2CC\C1=C\C(CC/1)=N\C\1=C/C(CC\1)=N/C/1=C\C1=NC2CC1 WUPRCGRRQUZFAB-DEGKJRJSSA-N 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000009195 dark therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000708 deep reactive-ion etching Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000005276 holographic polymer dispersed liquid crystals (HPDLCs) Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000000025 interference lithography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 230000004386 ocular blood flow Effects 0.000 description 1
- 239000005392 opalescent glass Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004232 retinal microvasculature Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/20—Filters
- G02B5/22—Absorbing filters
- G02B5/223—Absorbing filters containing organic substances, e.g. dyes, inks or pigments
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/104—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses having spectral characteristics for purposes other than sun-protection
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/20—Filters
- G02B5/28—Interference filters
- G02B5/285—Interference filters comprising deposited thin solid films
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/024—Methods of designing ophthalmic lenses
- G02C7/027—Methods of designing ophthalmic lenses considering wearer's parameters
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/105—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses having inhomogeneously distributed colouring
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/107—Interference colour filters
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/108—Colouring materials
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C2202/00—Generic optical aspects applicable to one or more of the subgroups of G02C7/00
- G02C2202/10—Optical elements and systems for visual disorders other than refractive errors, low vision
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Eyeglasses (AREA)
- Optical Filters (AREA)
- Eye Examination Apparatus (AREA)
- Prostheses (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306631.0 | 2011-12-08 | ||
EP11306631.0A EP2602654B1 (en) | 2011-12-08 | 2011-12-08 | Ophthalmic filter |
CN201280060062.0A CN103998974B (zh) | 2011-12-08 | 2012-12-06 | 光学器件 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280060062.0A Division CN103998974B (zh) | 2011-12-08 | 2012-12-06 | 光学器件 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106842617A true CN106842617A (zh) | 2017-06-13 |
Family
ID=47522764
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710022994.0A Pending CN106842617A (zh) | 2011-12-08 | 2012-12-06 | 光学器件 |
CN201280060062.0A Active CN103998974B (zh) | 2011-12-08 | 2012-12-06 | 光学器件 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280060062.0A Active CN103998974B (zh) | 2011-12-08 | 2012-12-06 | 光学器件 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140300857A1 (zh) |
EP (1) | EP2602654B1 (zh) |
JP (3) | JP2015507217A (zh) |
KR (1) | KR20140104998A (zh) |
CN (2) | CN106842617A (zh) |
AU (4) | AU2012348560B2 (zh) |
BR (1) | BR112014013881B1 (zh) |
WO (1) | WO2013084177A1 (zh) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047724A1 (en) | 2012-09-26 | 2014-04-03 | Ledtech International Inc. | Multilayer optical interference filter |
CA2828687C (en) * | 2013-10-01 | 2021-03-23 | Iridian Spectral Technologies Ltd. | Laser protective device with reflecting filter on non-absorbing and absorbing substrates |
US9885885B2 (en) | 2013-11-27 | 2018-02-06 | 3M Innovative Properties Company | Blue edge filter optical lens |
CN105829798B (zh) * | 2013-12-23 | 2019-09-10 | 依视路国际公司 | 具有滤光功能的头戴式显示器 |
US9739916B2 (en) * | 2014-03-20 | 2017-08-22 | 3M Innovative Properties Company | Circadian rhythm optical film |
US11065468B2 (en) * | 2014-09-03 | 2021-07-20 | Essilor International | Optical device |
US9529246B2 (en) | 2015-01-20 | 2016-12-27 | Microsoft Technology Licensing, Llc | Transparent camera module |
FR3039659B1 (fr) * | 2015-07-28 | 2018-08-17 | Essilor International | Lentille ophtalmique et procede de fabrication associe |
CN106543372A (zh) * | 2015-09-18 | 2017-03-29 | 鸿富锦精密工业(深圳)有限公司 | 眼用镜片材料、眼用镜片及人工晶状体 |
WO2017077358A1 (en) | 2015-11-06 | 2017-05-11 | Essilor International (Compagnie Générale d'Optique) | Optical article protecting from blue and uv light |
CN108235740B (zh) | 2015-11-06 | 2020-07-14 | 依视路国际公司 | 保护免受蓝光的光学制品 |
CN108603958B (zh) | 2016-01-21 | 2022-03-04 | 3M创新有限公司 | 光学掩蔽滤光器 |
TW201738588A (zh) * | 2016-01-21 | 2017-11-01 | 3M新設資產公司 | 偽裝濾光片 |
CA3010331C (en) | 2016-02-22 | 2021-06-22 | Novartis Ag | Uv-absorbing vinylic monomers and uses thereof |
US10268053B2 (en) | 2016-02-22 | 2019-04-23 | Novartis Ag | UV/visible-absorbing vinylic monomers and uses thereof |
WO2017180828A1 (en) * | 2016-04-13 | 2017-10-19 | Everix, Inc. | Eyewear article with interference filter |
FR3054683B1 (fr) * | 2016-07-26 | 2018-08-31 | Bnl Eurolens | Lentille ophtalmologique, notamment pour lunettes de soleil |
EP3491433A4 (en) * | 2016-07-28 | 2020-03-25 | Ronald S. Ace | SPECTRALLY SCULPTED MULTI-NARROW BAND FILTRATION TO IMPROVE HUMAN VISION |
EP3296799B1 (en) | 2016-09-20 | 2024-05-22 | Essilor International | Optical article with blue cut, high uv cut and high clarity |
US10962791B1 (en) | 2018-03-22 | 2021-03-30 | Facebook Technologies, Llc | Apparatuses, systems, and methods for fabricating ultra-thin adjustable lenses |
US11245065B1 (en) | 2018-03-22 | 2022-02-08 | Facebook Technologies, Llc | Electroactive polymer devices, systems, and methods |
US11048075B1 (en) | 2018-03-29 | 2021-06-29 | Facebook Technologies, Llc | Optical lens assemblies and related methods |
EP3564286A1 (en) | 2018-04-30 | 2019-11-06 | Essilor International | Blue light cutting optical material having a bluish appearance |
JP7144227B2 (ja) * | 2018-07-23 | 2022-09-29 | 三井化学株式会社 | レンズ、組成物およびレンズの製造方法 |
CN112840264B (zh) * | 2018-09-28 | 2023-03-14 | 豪雅镜片泰国有限公司 | 眼镜镜片 |
US11988902B2 (en) | 2018-09-28 | 2024-05-21 | Hoya Lens Thailand Ltd. | Spectacle lens |
US11256331B1 (en) | 2019-01-10 | 2022-02-22 | Facebook Technologies, Llc | Apparatuses, systems, and methods including haptic and touch sensing electroactive device arrays |
KR20210136017A (ko) | 2019-03-18 | 2021-11-16 | 에씰로 앙터나시오날 | 눈 원추 세포를 보호하기 위한 필터 |
EP3951349A4 (en) | 2019-03-27 | 2023-01-11 | IHI Corporation | LIGHTING RATING DEVICE, AND LIGHTING RATING METHOD |
US11583388B2 (en) | 2019-04-05 | 2023-02-21 | Amo Groningen B.V. | Systems and methods for spectacle independence using refractive index writing with an intraocular lens |
US11678975B2 (en) | 2019-04-05 | 2023-06-20 | Amo Groningen B.V. | Systems and methods for treating ocular disease with an intraocular lens and refractive index writing |
US11564839B2 (en) | 2019-04-05 | 2023-01-31 | Amo Groningen B.V. | Systems and methods for vergence matching of an intraocular lens with refractive index writing |
US11583389B2 (en) | 2019-04-05 | 2023-02-21 | Amo Groningen B.V. | Systems and methods for correcting photic phenomenon from an intraocular lens and using refractive index writing |
US11529230B2 (en) | 2019-04-05 | 2022-12-20 | Amo Groningen B.V. | Systems and methods for correcting power of an intraocular lens using refractive index writing |
US11944574B2 (en) | 2019-04-05 | 2024-04-02 | Amo Groningen B.V. | Systems and methods for multiple layer intraocular lens and using refractive index writing |
JP7270195B2 (ja) * | 2019-04-19 | 2023-05-10 | 三井化学株式会社 | 光学材料、光学材料用重合性組成物、硬化物、光学材料、プラスチックレンズ、光学材料の製造方法及び使用方法 |
EP3754406A1 (en) * | 2019-06-21 | 2020-12-23 | Essilor International | Ophthalmic lens having a holographic mirror on a low-birefringence base lens |
EP3783420A1 (de) | 2019-08-21 | 2021-02-24 | Carl Zeiss Vision International GmbH | Brillenglas mit filterwirkung für blaues licht und brille |
EP3800626A1 (en) | 2019-10-03 | 2021-04-07 | Nokia Technologies Oy | Blue light reduction |
JP7417896B2 (ja) * | 2020-03-25 | 2024-01-19 | パナソニックIpマネジメント株式会社 | 色覚検査用フィルタ、色覚検査用器具及び眼鏡 |
CN117529674A (zh) | 2021-06-09 | 2024-02-06 | 依视路国际公司 | 具有反射蓝光的抗反射涂层的光学镜片 |
CN115039738A (zh) * | 2022-04-07 | 2022-09-13 | 南京大学 | 一种光子晶体薄膜在减缓线虫光毒害中的应用 |
CN114839798B (zh) * | 2022-04-11 | 2024-08-23 | 深圳先进技术研究院 | 基于薄膜光子晶体的结构色隐形眼镜及其制备方法 |
CN114953539A (zh) * | 2022-05-23 | 2022-08-30 | 王玺智 | 一种防控近视镜片的制作方法 |
EP4386470A1 (en) * | 2022-12-12 | 2024-06-19 | Essilor International | Optical design and spectral transmission optimization |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6955430B2 (en) * | 2001-12-11 | 2005-10-18 | Pratt Steven G | Blue blocking lens |
WO2010111499A1 (en) * | 2009-03-25 | 2010-09-30 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
US7854505B2 (en) * | 2006-03-15 | 2010-12-21 | The Board Of Trustees Of The University Of Illinois | Passive and active photonic crystal structures and devices |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4786125A (en) * | 1983-08-22 | 1988-11-22 | Farrand Optical Co. | Ocular protective apparatus |
WO1988002871A1 (en) * | 1986-10-16 | 1988-04-21 | Suntiger, Incorporated | Ultraviolet radiation and blue light blocking polarizing lens |
US4878748A (en) * | 1987-02-26 | 1989-11-07 | Suntiger, Inc. | Ultraviolet radiation and blue light blocking polarizing lens |
DE3734438A1 (de) | 1987-10-12 | 1989-04-27 | Ver Glaswerke Gmbh | Verfahren zur herstellung eines reflexionshologramms |
US4942102A (en) | 1988-01-15 | 1990-07-17 | E. I. Du Pont De Nemours And Company | Holographic optical elements having a reflection hologram formed in a photopolymer |
US5024909A (en) | 1988-01-15 | 1991-06-18 | E. I. Du Pont De Nemours And Company | Dry film process for altering wavelength response of holograms |
DE3837008A1 (de) * | 1988-10-31 | 1990-05-03 | Zeiss Carl Fa | Lichtschutzfilter |
US5699798A (en) * | 1990-08-10 | 1997-12-23 | University Of Washington | Method for optically imaging solid tumor tissue |
US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
EP0809126B1 (en) | 1995-11-24 | 2003-03-19 | Seiko Epson Corporation | Progressive spectacle lens with progressive surface and correction of astigmatism provided on the rear side of the lens |
US20040070726A1 (en) * | 2000-11-03 | 2004-04-15 | Andrew Ishak | Waterman's sunglass lens |
US8403478B2 (en) * | 2001-11-02 | 2013-03-26 | High Performance Optics, Inc. | Ophthalmic lens to preserve macular integrity |
US7255435B2 (en) * | 2001-12-11 | 2007-08-14 | Pratt Steven G | Blue blocking tens |
JP2003337308A (ja) * | 2002-05-17 | 2003-11-28 | Nikon-Essilor Co Ltd | 眼鏡レンズ発注システム、眼鏡レンズ受注システム、眼鏡レンズ提供システム、眼鏡レンズ発注プログラム、眼鏡レンズ受注プログラム |
US7677725B2 (en) * | 2004-04-05 | 2010-03-16 | Amo Groningen B.V. | Ophthalmic lenses capable of reducing chromatic aberration |
CN2713500Y (zh) * | 2004-04-12 | 2005-07-27 | 温州众生科技有限公司 | 防蓝光伤害保健眼镜片 |
US20070216861A1 (en) * | 2006-03-20 | 2007-09-20 | Andrew Ishak | Ophthalmic system combining ophthalmic components with blue light wavelength blocking and color-balancing functionalities |
US8882267B2 (en) * | 2006-03-20 | 2014-11-11 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US9377569B2 (en) * | 2006-03-20 | 2016-06-28 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
US8360574B2 (en) * | 2006-03-20 | 2013-01-29 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
BRPI0715849B1 (pt) * | 2006-08-23 | 2021-12-28 | High Performance Optics, Inc | Sistema e método para inibição seletiva da luz |
CA2705785A1 (en) * | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
FR2908897B1 (fr) * | 2006-11-17 | 2009-03-06 | Essilor Int | Lentilles ophtalmiques colorees multi-teintes. |
AU2007325483B2 (en) * | 2006-11-28 | 2013-08-29 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
DE102007007777A1 (de) * | 2006-11-29 | 2008-06-05 | Eckhart Watzke | Verfahren für gesundes Sehen sowie optische Filter und deren Verwendung |
AU2008216683B2 (en) * | 2007-02-15 | 2014-05-01 | The Uab Research Foundation | Improved photobleaching method |
JP2010534350A (ja) * | 2007-07-20 | 2010-11-04 | ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ | 光誘導性損傷から網膜を保護するための方法およびシステム |
CN101821663B (zh) | 2007-10-10 | 2012-02-08 | Hoya株式会社 | 渐进多焦镜片的制造方法和渐进多焦镜片 |
JP5448352B2 (ja) * | 2008-03-10 | 2014-03-19 | 富士フイルム株式会社 | 着色硬化性組成物、カラーフィルタ、及び、固体撮像素子 |
ES2334960A1 (es) * | 2008-06-11 | 2010-03-17 | Universidad De Valladolid | Dispositivo de ayuda y proteccion en la vision. |
US20100149483A1 (en) * | 2008-12-12 | 2010-06-17 | Chiavetta Iii Stephen V | Optical Filter for Selectively Blocking Light |
US8002404B2 (en) * | 2009-05-22 | 2011-08-23 | Polylite Taiwan Co., Ltd. | Prescription lens and method of making same |
CN101776776A (zh) * | 2010-01-14 | 2010-07-14 | 北京大学第三医院 | 分色眼镜片及其制备方法 |
JP5619472B2 (ja) * | 2010-05-13 | 2014-11-05 | 山本化成株式会社 | 眼鏡レンズ |
-
2011
- 2011-12-08 EP EP11306631.0A patent/EP2602654B1/en active Active
-
2012
- 2012-12-06 US US14/363,905 patent/US20140300857A1/en not_active Abandoned
- 2012-12-06 AU AU2012348560A patent/AU2012348560B2/en active Active
- 2012-12-06 JP JP2014545429A patent/JP2015507217A/ja active Pending
- 2012-12-06 CN CN201710022994.0A patent/CN106842617A/zh active Pending
- 2012-12-06 CN CN201280060062.0A patent/CN103998974B/zh active Active
- 2012-12-06 WO PCT/IB2012/057014 patent/WO2013084177A1/en active Application Filing
- 2012-12-06 KR KR1020147018704A patent/KR20140104998A/ko active Search and Examination
- 2012-12-06 BR BR112014013881-8A patent/BR112014013881B1/pt active IP Right Grant
-
2016
- 2016-06-22 AU AU2016204243A patent/AU2016204243A1/en not_active Abandoned
-
2018
- 2018-05-17 AU AU2018203487A patent/AU2018203487A1/en not_active Abandoned
- 2018-08-27 JP JP2018158399A patent/JP2019061232A/ja active Pending
-
2020
- 2020-06-04 AU AU2020203703A patent/AU2020203703A1/en not_active Abandoned
- 2020-09-14 JP JP2020153707A patent/JP2020204785A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6955430B2 (en) * | 2001-12-11 | 2005-10-18 | Pratt Steven G | Blue blocking lens |
US7854505B2 (en) * | 2006-03-15 | 2010-12-21 | The Board Of Trustees Of The University Of Illinois | Passive and active photonic crystal structures and devices |
WO2010111499A1 (en) * | 2009-03-25 | 2010-09-30 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
Non-Patent Citations (3)
Title |
---|
STEPHEN ZHOU: ""蓝光伤害"与眼镜防护保健", 《中国眼镜科技杂志》 * |
李青等: "蓝光对视觉功能的利与弊", 《国际眼科纵览》 * |
郭菲: "与蓝光谱丰富的白光室外照明相关的视觉、环境及天文问题(续一)", 《光源与照明》 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018203487A1 (en) | 2018-06-07 |
AU2012348560B2 (en) | 2016-03-24 |
CN103998974B (zh) | 2017-02-22 |
AU2020203703A1 (en) | 2020-06-25 |
AU2016204243A1 (en) | 2016-07-14 |
JP2019061232A (ja) | 2019-04-18 |
BR112014013881B1 (pt) | 2023-09-26 |
US20140300857A1 (en) | 2014-10-09 |
CN103998974A (zh) | 2014-08-20 |
KR20140104998A (ko) | 2014-08-29 |
WO2013084177A1 (en) | 2013-06-13 |
JP2015507217A (ja) | 2015-03-05 |
JP2020204785A (ja) | 2020-12-24 |
BR112014013881A8 (pt) | 2017-06-13 |
AU2012348560A1 (en) | 2014-07-17 |
EP2602654B1 (en) | 2023-04-19 |
EP2602654A1 (en) | 2013-06-12 |
BR112014013881A2 (pt) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103998974B (zh) | 光学器件 | |
CN104024924B (zh) | 确定干涉滤光装置的配置的方法和制造光学镜片的方法 | |
CN104115054B (zh) | 眼科滤光片 | |
ES2984462T3 (es) | Aparato para reducir la frecuencia y/o gravedad de las respuestas fotofóbicas o para modular los ciclos circadianos | |
JP7281204B2 (ja) | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 | |
CN107272223A (zh) | 提供改进的对比灵敏度的高性能选择性光波长过滤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180409 Address after: France Sharon Ton Le Pon Applicant after: Essilor International Ltd. Applicant after: Universite Pierre et Marie Curie, Paris Vi Address before: France Sharon Ton Le Pon Applicant before: Essilor International General Optical Co., Ltd. Applicant before: Universite Pierre et Marie Curie, Paris Vi |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190226 Address after: France Sharon Ton Le Pon Applicant after: Essilor International Ltd. Applicant after: Sorbonne University Address before: France Sharon Ton Le Pon Applicant before: Essilor International Ltd. Applicant before: Universite Pierre et Marie Curie, Paris Vi |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |